The significance of Hippo pathway protein expression in oral squamous cell carcinoma.

Hippo pathway MST1/2 PRMT YAP1 oral squamous cell carcinoma

Journal

Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047

Informations de publication

Date de publication:
2024
Historique:
received: 26 06 2023
accepted: 06 02 2024
medline: 6 3 2024
pubmed: 6 3 2024
entrez: 6 3 2024
Statut: epublish

Résumé

The Hippo pathway consists of mammalian sterile 20-like kinase 1/2 (MST1/2), large tumor suppressor 1/2 (LATS1/2), and yes-associated protein (YAP)1. Herein, we present the first report on the significance of major Hippo pathway protein expression in oral squamous cell carcinoma (OSCC). The analyses included oral epithelial dysplasia (OED, Cytoplasmic expression of MST1, LATS1, and LATS2 was low in OED, CIS, and OSCC. The cytoplasmic expression of MST2 was high in OED (5/7 cases), CIS (9/14 cases), and poorly differentiated OSCC (8/8 cases) but was low/lost in a proportion of differentiated OSCC (60/101 cases). The expression of YAP1 was associated with differentiation; low YAP expression was significantly more frequent in well-differentiated OSCC (35/71 cases), compared to moderately and poorly differentiated OSCC (11/38 cases). An infiltrative invasion pattern was associated with a high expression of MST2 and high expression of YAP1. The high expression of YAP1 was associated with features of epithelial-to-mesenchymal transition (EMT), such as the loss of E-cadherin and high expression of vimentin, laminin 5, and Slug. High expression of protein arginine methyltransferase (PRMT) 1 or 5, which positively regulates YAP activity, was associated with the high expression of YAP1 ( Among the major Hippo pathway proteins, MST2 displayed a distinctive expression pattern in a significant proportion of differentiated OSCC, suggesting a possible differential role for MST2 depending on the course of OSCC progression. A high YAP1 expression may indicate aggressive OSCC with EMT via PRMTs at the invasive front.

Identifiants

pubmed: 38444414
doi: 10.3389/fmed.2024.1247625
pmc: PMC10912186
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1247625

Informations de copyright

Copyright © 2024 Amano, Matsubara, Kihara, Yoshimoto, Fukushima, Nishino, Mori and Niki.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Yusuke Amano (Y)

Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.

Daisuke Matsubara (D)

Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.
Department of Diagnostic Pathology, University of Tsukuba, Tsukuba, Japan.

Atsushi Kihara (A)

Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.

Taichiro Yoshimoto (T)

Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.

Noriyoshi Fukushima (N)

Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.

Hiroshi Nishino (H)

Department of Otolaryngology, Jichi Medical University, Shimotsuke, Japan.

Yoshiyuki Mori (Y)

Department of Dentistry, Oral and Maxillofacial Surgery, Saitama Medical Center Jichi Medical University, Saitama, Japan.

Toshiro Niki (T)

Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.

Classifications MeSH